

SHORT COMMUNICATION

Telomere and a Final Verdict for Cellular Senescence

Aye Aye Wynn*, Nang Khin Mya

¹ Department of Pathology and Medical Diagnostics, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia

*Corresponding author's email: drwynnaa@ums.edu.my

Received: 19 February 2020

Accepted: 16 July 2020

Keywords: telomere, cellular senescence, eukaryotic cells, tumourigenesis

ABSTRACT

Telomeres are specialized DNA complexes found at the end of all chromosomes. Human, as a member of eukaryotic cells, requires telomeres to maintain the length and the stability of chromosomes. Telomeres lose their non-coding DNA sequence to protect the genetic information on the chromosomes. Shortening of telomeres occurs in most somatic cells after sufficient cell division in a human lifetime. Normal haemopoietic cells or stem cells possess telomerase enzyme to restore telomeres and allow further replication. Telomere dysfunction is the origin of several degenerative disorders and also predispose to cancer. Roles of telomere in carcinogenesis and ageing related disorders are reviewed.

INTRODUCTION

Telomeres are repetitive (TTAGGG) DNA-protein complexes at the ends of chromosomes. Shortening of telomere is one of the mechanisms of replicative senescence¹. During replication of somatic cells, a portion of telomere is not duplicated and it becomes shorter. Telomerase enzyme is a specialised RNA-protein complex which is composed of reverse transcriptase (hTERT) and an RNA subunit (hTER)². Telomerase can use its RNA as templates to add nucleotides to the end of chromosome preventing the shortening. Normal somatic cells do not express it; hence have limited replication capacity resulting in replicative senescence activation.

Telomere and Cancer

Majority of cancer cells express telomerase to maintain chromosome length to become immortal. This activity is crucial for the survival of cancer cells³. In other instances, telomeres in cancer cells become extremely short and form *t*-stumps. Many chromosomal instability characteristics of human cancer cells result from *t*-stumps. In tumour cells positive for telomerase, these short *t*-stumps are regenerated, stabilized or protected from elimination by the hTERT⁴. Several methods measure telomere length (TL) namely: quantitative polymerase chain reaction, terminal restriction fragment length analysis, quantitative fluorescent in situ hybridization, telomere dysfunctional induced foci analysis, single telomere length analysis, telomere shortest length assay⁵. Telomere Restriction Fragment (TRF) analysis is the gold standard for measurement of telomere⁶.

Telomere length and telomerase activity play important role in tumourigenesis and immortality of cancer cells. Studies showed short or eroded telomeres accounted for ~73% of the 125 colorectal cancers (CRCs) analysed whereas ~27% of the tumours showed unchanged or elongated telomeres. The survival rate is better in length-maintained colorectal cancers compared to those with eroded or shortened telomeres⁷. Cancer cell expresses constitutive telomerase reverse transcriptase (TERT) expression. Overexpress TERT is seen in many cancers including colorectal cancer⁸, bladder cancer⁹, ovarian and lung cancer¹⁰.

Downregulation of telomere-related genes is useful in gene therapy for cancers. Knockdown of telomerase RNA (hTER) leads to rapid growth inhibition of cancer cells¹¹. Efforts to target telomerase showed that the activity of tumour telomerase becomes attenuated resulting in reduced survival of cancer cells¹². Personalised genetic therapies which modify inhibitory effects of telomerase are reliable alternatives for effective treatment of cancer in the future.

Telomere and Degenerative Diseases

Telomere attrition is responsible for degenerative or ageing disorders¹³. There is an association between short leukocyte telomere length and cardiovascular risk factors, such as smoking, obesity, and hypertension¹⁴. Germline mutation of TERT is associated with idiopathic pulmonary fibrosis, emphysema and dyskeratosis congenita¹⁵.¹⁶ Telomere length seems to have a key role in cardiovascular disease contributed by vascular ageing¹⁷. Induction of telomerase gene expression benefits regeneration after cardiac injury by inhibiting the apoptosis of cardiac myocytes. Also, a similar study showed survival of vascular lining endothelial cells and smooth muscles preventing the age-related disorders¹³. Autopsy findings revealed significantly short telomere in the hippocampus of major depressive disorders suggesting the evidence of stress-mediated accelerated cellular ageing in depression¹⁸. Telomere attrition was seen in the beta cell of the pancreas in type 2 diabetic patients with poor glycaemic control autopsied pancreas¹⁹. Some factors, such as oxidative stress, result in the accelerated shortening of telomere and diminish the survival of cells leading to cardiomyopathy and atherosclerosis²⁰. Defect telomerase RNA is associated with aplastic anaemia²¹. Experimental study on Tert-gene knock out mice treated with Tert-gene therapy showed an increase in peripheral blood count and bone marrow haemopoietic cells in previously aplastic marrow²². In advanced liver cirrhosis and idiopathic pulmonary, the fibrotic process can be reversed by transfer of telomerase gene²³. Experimental expression of telomere maintenance genes or telomerase is helpful for diseases associated with shortening of telomere. Non-integrative expression of these genes does not promote oncogenesis²⁴. However, the potential risk of carcinogenesis by upregulation of telomerase should be studied in long term basis²⁵.

CONCLUSION

Telomere shortening is a natural process that all somatic cells must undergo. Some exceptional cells such as marrow stem cells and haemopoietic cells have their mechanism to maintain their telomere length to sustain their function throughout life. Modification of telomere-related genes is helpful in anti-ageing, antifibrotic or anticancer therapies. Further research on the mechanism of telomere related tumour genesis and its relationship with genomic change is essential for clinical application. Modifying genes that control telomerase and its use as a therapy has a significant role in comprehensive control of tumour progression in a variety of neoplasms.

REFERENCES

1. Armstrong C, Tomita K. (2017). Fundamental mechanisms of telomerase action in yeasts and mammals: understanding telomeres and telomerase in cancer cells. *Open Biol* 7 (3): 1 – 13. DOI: doi.org/10.1098/rsob.160338
2. Arminos M, Blackburn EH. (2012). The telomere syndromes. *Nat. Rev. Genet* 13: 693 – 704. DOI: https://doi: 10.1038/nrg3246
3. Jafri MA, Ansari SA, Alqahtani MH, Shay JW. (2016). Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. *Genome Med* 8 (69): 1 – 18. DOI: https://doi: 10.1186/s13073-016-0324-x
4. Xu L, Blackburn EH. (2007). Human cancer cells harbor t-stumps, a distinct class of extremely short telomeres. *Mol. Cell* 28: 315 – 327. DOI: https://doi: 10.1016/j.molcel.2007.10.005
5. Lai TS, Wright WE, Shay JW. (2018). Comparison of telomere length measurement methods. *Phil Trans R Soc B* 373: 1 – 10. DOI: http:// dx.doi.org/10.1098/rstb.2016.0451
6. Aubert G, Hills M, Lansdorp PM. (2012) Telomere length measurement – Caveats and a critical assessment of the available technologies and tools. *Mut. Res* 730: 59 – 67. DOI: https://doi: 10.1016/j.mrfmmm.2011.04.003
7. Balcih EL, Grandin N, Demattei MV et al. (2017). Measurement of telomere length in colorectal cancers for improved molecular diagnosis. *Int J Mol Sci* 18 (9): 1871. DOI: https://doi: 10.3390/ijms18091871
8. Higashi K, Hazama S, Araki A et al. (2014). A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model. *Int. J. Oncol* 45: 1412 – 1420. DOI: https://doi: 10.3892/ijo.2014.2557
9. Liu L, Liu Y, Zhang T et al. (2016). Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer. *J Exp Clin Cancer Res* 8 (35): 3. DOI: https://doi: 10.1186/s13046-015-0279-6
10. Barthel FP, Wei W, Tang, M et al. (2017). Systematic analysis of telomere length and somatic alterations in 31 cancer types. *Nat Genet* 49 (3): 349 – 357.
11. Lim S, Rosenberg JE, Donjacour AA et al. (2004). Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. *Cancer Res* 64 (14): 4833 – 4840.
12. Kosciolk BA, Kalantidis K, Tabler M, Rowley PT. (2003). Inhibition of telomerase activity in human cancer cells by RNA interference. *Mol. Cancer Ther* 2: 209 – 216.
13. Hong J, Yun CO. (2019). Telomere gene therapy: Polarizing therapeutic goals for treatment of various diseases. *Cells* 8 (5): 392. DOI: https://doi:10.3390/cells8050392
14. Yeh JK., Wang CY. (2016). Telomeres and telomerase in cardiovascular diseases. *Genes* 7: 58. DOI: https://doi: 10.3390/genes7090058
15. Colebatch AJ, Dobrovic A, Cooper WA. (2019). *TERT* gene: Its function and dysregulation in cancer. *Journal of Clinical Pathology* 72: 281 – 284.
16. Stanley SE, Chen JJ, Podlevsky JD et al. (2015). Telomerase mutations in smokers with severe emphysema. *J Clin Invest* 125: 563 – 570. DOI: 10.1172/JCI78554
17. Kovacic JC, Moreno P, Hachinski V et al. (2011). Cellular senescence, vascular disease, and aging. Part 1 of a 2-Part Review. *Circulation* 123: 1650 – 1660.

18. Mamdani F, Rollins B, Morgan L et al. (2016). Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. *Transl Psychiatry* 5 (9): e636. DOI: 10.1038/tp.2015.134.
19. Mamdani F, Rollins B, Morgan L. (2016). Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. *Transl Psychiatry* 6 (12): e969.
20. Tamura Y, Shimomura N, Kimbara Y et al. (2014). β -cell telomere attrition in diabetes: Inverse correlation between HbA1c and telomere length. *The Journal of Clinical Endocrinology & Metabolism* 99 (8): 2771 – 2777. DOI: <https://doi.org/10.1210/jc.2014-1222>
21. Khan SJ, Pham S, Wei Y et al. (2010). Stress-induced senescence exaggerates post injury neointimal formation in the old vasculature. *Am J Physiol Heart Circ Physiol* 29: 66 – 74.
22. Vulliamy T, Marrone A, Dokal I, Mason PJ. (2002) Association between aplastic anaemia and mutations in telomerase RNA. *Lancet* 359 (9324): 2168 – 2170.
23. Bar C, Povedano JM, Serrano R et al. (2016). Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. *Blood* 127: 1770 – 1779. DOI: 10.1182/blood-2015-08-667485
24. Rudolph KL, Chang S, Millard M et al. (2000). Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. *Science* 287: 1253 – 1258. DOI: 10.1126/science.287.5456.1253
25. Bernardes de Jesus B, Vera E, Schneeberger K et al. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. *EMBO Mol Med* 4: 691 – 704.